Tumor necrosis factor-α induces proliferation and reduces apoptosis of colorectal cancer cells through STAT3 activation

[1]  A. Lesokhin,et al.  Immunotherapy , 2016, Advances in Experimental Medicine and Biology.

[2]  M. Karin,et al.  Immunotherapy, Inflammation and Colorectal Cancer , 2020, Cells.

[3]  A. Bonetto,et al.  HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia , 2020, Disease Models & Mechanisms.

[4]  G. Kollias,et al.  STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis , 2019, Gut.

[5]  Juan Ma,et al.  Amorfrutin A inhibits TNF-α induced JAK/STAT signaling, cell survival and proliferation of human cancer cells , 2017, Immunopharmacology and immunotoxicology.

[6]  Jian-Ming Hou,et al.  Roscovitine attenuates intimal hyperplasia via inhibiting NF‐&kgr;B and STAT3 activation induced by TNF‐&agr; in vascular smooth muscle cells , 2017, Biochemical pharmacology.

[7]  L. Ye,et al.  Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1 , 2017, Oncotarget.

[8]  L. Ye,et al.  Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1 , 2017, Oncotarget.

[9]  K. Simon.  Colorectal cancer development and advances in screening , 2016, Clinical interventions in aging.

[10]  P. Krebs,et al.  Cytokine-Induced Modulation of Colorectal Cancer , 2016, Front. Oncol..

[11]  W. Strober,et al.  Chronic inflammation and the development of malignancy in the GI tract. , 2015, Trends in immunology.

[12]  Nigel J Gooderham,et al.  IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b , 2015, Molecular Cancer Research.

[13]  F. Balkwill,et al.  Inflammation and cancer: advances and new agents , 2015, Nature Reviews Clinical Oncology.

[14]  C. Qian,et al.  Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition , 2015, Carcinogenesis.

[15]  T. Macdonald,et al.  Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth , 2014, Oncogene.

[16]  J. McKerrow,et al.  Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. , 2014, World journal of gastroenterology.

[17]  M. Wang,et al.  Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C , 2014, Cancer science.

[18]  H. Ji,et al.  TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling , 2014, Nature Communications.

[19]  L. Miteva,et al.  Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha , 2014, Biotechnology, biotechnological equipment.

[20]  H. Saya,et al.  TNF-α/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells , 2014, Oncogene.

[21]  Mikinori Sato,et al.  Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction , 2013, British Journal of Cancer.

[22]  K. Sun,et al.  Inhibition of tumor necrosis factor alpha reduces the outgrowth of hepatic micrometastasis of colorectal tumors in a mouse model of liver ischemia-reperfusion injury , 2014, Journal of Biomedical Science.

[23]  J. Maciejewski,et al.  Inhibition Of The JAK/STAT Signaling Pathway As a Novel Therapy In CD8+ T-Large Granular Lymphocyte Leukemia , 2013 .

[24]  G. K. Gray,et al.  NF-κB-Induced IL-6 Ensures STAT3 Activation and Tumor Aggressiveness in Glioblastoma , 2013, PloS one.

[25]  J. Comella,et al.  TNFα induces survival through the FLIP-L-dependent activation of the MAPK/ERK pathway , 2013, Cell Death and Disease.

[26]  S. Rose-John.  IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 , 2012, International journal of biological sciences.

[27]  S. Rose-John,et al.  Therapeutic Blockade of Interleukin‐6 in Chronic Inflammatory Disease , 2012, Clinical pharmacology and therapeutics.

[28]  S. Itzkowitz,et al.  Intestinal inflammation and cancer. , 2011, Gastroenterology.

[29]  M. Karin,et al.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.

[30]  Joyce Tse.  Inhibition of STAT3 decreases OSM induced EDA-FN expression in human lung fibroblasts , 2011 .

[31]  M. Grimm,et al.  Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment , 2011, Cellular Oncology.

[32]  T. Tuohy,et al.  Hereditary and familial colon cancer. , 2010, Gastroenterology.

[33]  Y. Wu,et al.  TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion , 2010, British Journal of Cancer.

[34]  S. Kenney,et al.  CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter. , 2009, Molecular immunology.

[35]  N. Sakamoto,et al.  Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[36]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[37]  S. Groshen,et al.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. , 2009, Cancer research.

[38]  D. Donner,et al.  Type 1 TNF Receptor Forms a Complex with and Uses Jak2 and c-Src to Selectively Engage Signaling Pathways That Regulate Transcription Factor Activity1 , 2008, The Journal of Immunology.

[39]  Kaneko,et al.  Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis , 2008 .

[40]  B. Aggarwal,et al.  Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-κB activation and proliferation in human head and neck squamous cell carcinoma , 2007, Oncogene.

[41]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[42]  Wei Zhang,et al.  Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. , 2005, The American journal of pathology.

[43]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[44]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[45]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Love,et al.  Survival Analysis Part III: Multivariate data analysis – choosing a model and assessing its adequacy and fit , 2003, British Journal of Cancer.

[47]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[48]  T. Lightfoot,et al.  Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκB kinase-α in human colorectal cancer epithelial cells , 2003, British Journal of Cancer.

[49]  A. Ammit,et al.  Tumor Necrosis Factor Receptor (TNFR) 1, but Not TNFR2, Mediates Tumor Necrosis Factor- –Induced Interleukin-6 and RANTES in Human Airway Smooth Muscle Cells: Role of p38 and p42/44 Mitogen-Activated Protein Kinases , 2001 .

[50]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[51]  D. Thuerauf,et al.  p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. , 2000, The Journal of biological chemistry.

[52]  M. Ryan,et al.  Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells. , 1999, Kidney international.

[53]  L. Pfeffer,et al.  Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. , 1998, Journal of immunology.

[54]  N. Thornberry,et al.  Caspases: killer proteases. , 1997, Trends in biochemical sciences.

[55]  J. Ihle.  STATs: Signal Transducers and Activators of Transcription , 1996, Cell.

[56]  J. Rüschoff,et al.  Enhancement of experimental metastasis by tumor necrosis factor , 1993, The Journal of experimental medicine.

[57]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[58]  D. de Silva.  Tumour necrosis factor , 1990, The Ceylon medical journal.